Genetic Analysis signs exclusive German distribution agreement with Labor Dr. Bayer/synlab for GA-map™ Dysbiosis test

OSLO--()--Mdx specialist, Genetic Analysis AS (Genetic Analysis) today announced it has signed an exclusive German distribution agreement for its GA-map™ Dysbiosis test with Labor Dr. Bayer/synlab a leading European Clinical Lab Service Provider operating in 23 countries in Europe and Middle East. Labor Dr. Bayer/synlab aims to access the growing German IBS population and will run the test in their own laboratories. As part of the agreement, Labor Dr. Bayer/synlab has also acquired a non-exclusive option for other selected European and Middle East markets.

“We are pleased to have reached an agreement with Labor Dr. Bayer/synlab, which is a leading provider of high quality Lab services to German and European doctors and hospitals. The agreement with Labor Dr. Bayer/synlab represents a commercial breakthrough for Genetic Analysis and a recognition of the quality of our GA-map™ technology. Germany, being the biggest market in Europe, will be of key importance for the broader European commercialization of our test,” says Kari Stenersen, CEO of Genetic Analysis.

“Genetic Analysis, through the GA-map™ Dysbiosis test, enables Labor Dr. Bayer/synlab to be the first provider in the German market of a CE marked IVD test for diagnosis of dysbiosis in IBS and IBD patients. Publications1 state that some 10-15% of the population in Germany suffer from IBS, and we see the GA-map™ Dysbiosis test as an important addition to our test program. Based upon this test I expect substantial improvement in the therapeutic management of these disorders.” Says Dr. Wolfgang Bayer, Head of Department Labor Dr. Bayer/synlab.

About Genetic Analysis

Genetic Analysis has developed and launched the first gene-based routine test for the mapping and diagnosis of diseases related to dysbiosis and imbalances in the bacteria in the digestive system. The company markets the GA-map™ technology to three market segments: commercial routine testing, pharma companies and the research market. Genetic Analysis was established in 2008 and is based on research done by Professor Knut Rudi at Norwegian University of Life Sciences, NMBU and Nofima Mat in Ås. www.genetic-analysis.com

About synlab

With headquarters in Augsburg, Germany, the synlab group is the leading provider of medical laboratory services in Europe. The company offers a full range of laboratory analyses and consultancy services for human and veterinary medicine as well as for the environment. In addition to Germany, synlab has branches in 23 European countries as well as in Turkey, Saudi Arabia and Dubai. The synlab group has a staff of approx. 7,000 across Europe including 4,500 employees in Germany. The 175 laboratories of the synlab group perform approx. 1 mio. tests every day and, in 2013, generated revenues of approx. EUR 700 million. For more information, visit www.synlab.de

1 The epidemiology of irritable bowel syndrome Clin Epidemiol. 2014; 6: 71–80

Contacts

Genetic Analysis
For further information, please contact:
CEO Kari Stenersen
Mobile: +47 48 32 16 20
E-mail: ks@genet-analysis.com

Release Summary

Genetic Analysis has signed a distribution agreement for its GA-map™ Dysbiosis test with Labor Dr. Bayer/synlab a leading European Clinical Lab Service Provider

Contacts

Genetic Analysis
For further information, please contact:
CEO Kari Stenersen
Mobile: +47 48 32 16 20
E-mail: ks@genet-analysis.com